Seven weeks after restrictions on Dr Andrew Amos, new FOI insights raise questions about AHPRA’s independence and whether regulatory process is becoming punishment.

When I published my earlier article on the Amos case in March, the immediate-action conditions imposed on Queensland psychiatrist Dr Andrew Amos had only just become public. Barely a week had passed since the Medical Board of Australia’s 26 February decision that restricted his ability to speak publicly on gender medicine and removed him from clinical practice.

Seven weeks later, those conditions remain. There has been no final hearing, no finding of misconduct, and no determination of patient harm.

In that time, the situation has evolved in ways that raise broader questions, not only about one doctor, but about how medical regulation operates in contested areas of practice.

As I noted in my previous article, I have also taken the step of engaging directly with the regulatory process through my own correspondence. That experience has reinforced that this is not simply an abstract policy issue, but one with real implications for how open debate is handled within the profession. It is for that reason that I continue to follow this case closely.

What has changed in recent days is significant.

The Royal Australian and New Zealand College of Psychiatrists (RANZCP) has now suspended Dr Amos’s membership, citing the restrictions placed on him by the regulator. At the same time, newly released Freedom of Information material has provided greater visibility into AHPRA’s formal partnership with the trans-health advocacy organisation ACON, raising fresh and legitimate questions about regulatory independence.

“Process as Punishment”: When Regulation Becomes the Penalty

Under the Health Practitioner Regulation National Law, the Medical Board has the power to take “immediate action” where it forms a reasonable belief that there may be a serious risk to public safety or to public confidence in the profession. Importantly, this threshold does not require a completed investigation or a finding of wrongdoing.

It is a power designed for urgent and exceptional circumstances.

In Dr Amos’s case, that power was exercised following complaints about his public commentary on the evidence base for puberty blockers and cross-sex hormones in minors.

The conditions imposed are described as “interim.” In practice, however, their effect is immediate and substantial. Dr Amos, a practising psychiatrist and academic with peer-reviewed work in this field, is effectively prevented from speaking publicly on the very topic in which he holds recognised expertise. His ability to practise clinically is also curtailed.

Some clinicians have begun to describe this dynamic as “the punishment is the process.”

Even if a full investigation ultimately clears him, the professional consequences, reputational damage, loss of income, legal costs, and institutional isolation are already in motion. The RANZCP’s decision to suspend his membership adds a further layer. Dr Amos has stated publicly that he was given no prior notice and no opportunity to respond before that decision was made.

How the System Works in Practice

Public discussion of this case has highlighted a common area of confusion: the respective roles of AHPRA and the Medical Board of Australia.

The current national regulatory framework was established in 2010 under the Health Practitioner Regulation National Law, bringing together previously state-based systems into a single, coordinated structure.

AHPRA was created as the administrative body, working alongside National Boards such as the Medical Board of Australia, with the stated aim of improving consistency, mobility of the workforce, and public safety across jurisdictions.

In doing so, however, the system also consolidated significant investigative and enforcement powers within a centralised model. The ability to impose immediate conditions, restrict practice, and shape professional standards, often prior to final findings, reflects a framework designed for efficiency and risk management, but one that places significant weight on early intervention.

As cases such as Dr Amos’s illustrate, it also raises important questions about how those powers are exercised, and how procedural safeguards keep pace with the scale of authority granted.

In simplified terms:

• AHPRA receives complaints, conducts investigations, gathers evidence, and prepares a report including findings and recommendations.

• The Medical Board of Australia reviews that material and makes the formal regulatory decision, whether to impose conditions, refer the matter to a tribunal, or take no further action.

In this case, as in others, AHPRA investigated and recommended; the Medical Board decided.

This structure is intended to provide both administrative efficiency and professional oversight. However, in practice, the Board’s reliance on AHPRA’s investigative work means the distinction can appear less independent than it is formally designed to be.

Emerging Questions Around Independence

Alongside the procedural issues, a separate concern has come into sharper focus in recent weeks.

Freedom of Information documents, reported in The Australian in late April, have provided greater visibility into AHPRA’s formal partnership with ACON and its involvement in the Rainbow Tick accreditation framework.

ACON is a well-established public health organisation with a long history in HIV prevention and LGBTIQA+ health advocacy. However, the question now being raised by critics is whether a national health regulator should be formally aligned with any single advocacy body in areas of ongoing scientific and clinical debate.

Internal correspondence reportedly indicates that AHPRA’s engagement with ACON and Rainbow Health Australia helps “guide the way we regulate and fulfil our purpose of ensuring public safety.”

Concerns of this nature have also been raised by some clinicians, including calls for greater scrutiny of how such relationships are managed and whether they give rise to perceived conflicts of interest.

These developments are unfolding at a time when international evidence reviews, most notably the Cass Review, have prompted a reassessment of treatment pathways for minors in several jurisdictions.

In that broader context, the question is not whether stakeholders should be consulted, they should, but whether a regulator’s formal alignment with particular advocacy frameworks risks undermining perceptions of neutrality in highly contested areas.

A further contextual layer, one I have touched on in previous writing and correspondence, is the extent to which regulatory thinking is shaped not only by domestic inputs, but by broader institutional and policy frameworks.

In earlier discussions around early childhood sexuality education standards, concerns were raised, not only by myself but by other observers, about how certain frameworks were being interpreted and applied within an Australian context.

In that light, AHPRA’s role as a World Health Organization (WHO) Collaborating Centre, and its participation in regional forums such as the Western Pacific Regulatory Network, becomes part of a wider question rather than a discrete issue.

These bodies are designed to support cooperation and consistency across jurisdictions, and the WHO does not direct national regulatory decisions. However, its guidance and policy frameworks can contribute to shaping the regulatory environment in which agencies operate.

For many, particularly in the wake of the COVID-19 period, where a number of practitioners were subject to regulatory action after publicly questioning aspects of vaccine policy or early treatment protocols, this is not viewed as an isolated development.

Rather, it is seen as part of an emerging pattern in which regulatory intervention intersects with areas of active scientific and policy debate.

In that context, a reasonable question follows: how should regulators balance global alignment with the need to demonstrate clear independence, proportionality, and accountability within their own national setting?

Why This Matters for Patients and Public Trust

The core question remains the same as it was in March:

In an area of genuine scientific uncertainty, does restricting the public contribution of qualified experts enhance public safety, or does it risk narrowing the scope of legitimate clinical debate?

Dr Amos is not the only clinician to face regulatory scrutiny in this space. At the same time, questions are increasingly being asked about whether scrutiny is being applied consistently across differing clinical perspectives.

Public trust in health regulation is not automatic. It depends on transparency, procedural fairness, and a clear demonstration of impartiality.

When interim processes carry significant professional consequences before findings are made, and when questions about external influence remain unresolved, that trust is inevitably tested.

Seven weeks on, the Amos case has moved beyond a single regulatory decision. It now serves as a broader illustration of how medical governance functions when science, ethics, and public policy intersect.

Whatever the eventual outcome of the investigation, the interim consequences, and the institutional relationships now in view, warrant careful and ongoing scrutiny.

The pursuit of child and adolescent health should not be subordinated to any ideology. It requires open, evidence-based engagement between qualified professionals.

If the regulatory environment makes that engagement professionally risky, the ultimate cost will not be borne by clinicians, but by the patients the system is intended to protect.

As the interim restrictions on Dr Andrew Amos stretch into their eighth week and the regulatory machinery continues its work without a finding of harm, Proverbs 31:8-9 rings with undiminished clarity:

“Speak up for those who cannot speak for themselves, for the rights of all who are destitute. Speak up and judge fairly; defend the rights of the poor and needy.”

These are the very minors, often already burdened by mental-health struggles, autism, or social contagion, who cannot stand in the hearing rooms of AHPRA or the RANZCP to plead for evidence-based caution.

In silencing a qualified psychiatrist whose peer-reviewed work calls for precisely that caution, the system does not merely discipline one doctor; it leaves the weakest without an advocate.

Yet the command remains: speak up, and judge fairly. Not with reckless noise, but with the steady, data-driven voice Dr Amos has modelled.

In the unseen battle of Ephesians 6:12, may the Lord raise up many more such voices, shrewd as serpents, innocent as doves, until every child entrusted to our care receives the protection their youth and their future demand.